|
News and Events:
Breakthrough MultiTag Sequencing™ Primers and Services Now Available for Metagenomics Research
Advanced MultiTag Sequencing™ primer kits and full line of pyrosequencing services are now available from Metabiomics™ LLC to the Microbiome research community to increase throughput, productivity, and comparative statistical analysis, differentiating subject populations, samples, and/or characteristics. MultiTag Sequencing™ enables researchers to barcode DNA samples by source which can then be economically sequenced in a single massively parallel pyrosequencing run and then, using bioinformatics and statistical tools, to perform multivariate statistical techniques to perform comparative analysis of sample characteristics, dependent, and independent variables of interest.
MultiTag Sequencing™ Patent Application Advances to National Phase - Manassas, VA (April 15, 2009)
Metabiomics™ LLC announced that it received a favorable International Preliminary Report on Patentability from the Patent Cooperation Treaty (PCT) on its application to patent its enabling MultiTag Sequencing™ (MTPS) method for unique identification of multiple samples processed in single or consolidated high throughput DNA sequencing runs. The technology covers all non-electrophoretic DNA sequencing methodologies.
The new MTPS method enables unique tagging and identification of multiple DNA samples allowing subsequent statistical analysis of large datasets. The method is particularly useful for clinical trials where each sample can be associated with specific disease classes participating in the trial. Other uses include differentiating samples by geospatial location or ecological source allowing subsequent statistical analysis and correlation with other environmental data associated with the specific sample.
Following through on the favorable PCT patentability report, Metabiomics™ LLC has initiated the Nationalization Phase of the application process worldwide and is represented by Millen, White, Zelano & Branigan, PC in Arlington, Virginia.
New Microbiome Research Center Adopts MultiTag Sequencing™ Technology
Manassas, VA (April 15, 2009) – The newly organized MicroBiome Analysis Center (MBAC) at George Mason University has partnered with Metabiomics™ LLC to map the world that bacteria, viruses, fungi and protozoa inhabit the human body called the Human Microbiome. The MBAC has adopted Metabiomics™ LLC patent pending MultiTag Sequencing™ technology for the analysis of complex microbial systems under a on-going collaborative R&D agreement.
Dr. Patrick Gillevet is co-founder of Metabiomics™ LLC and is also an Associate Professor at GMU and Director of MBAC. Gillevet, developed and patented a technology for genomic sequencing in 2006 called MultiTag Sequencing™ (MTPS) that allows researchers to examine, count and barcode hundreds of thousands of microorganisms per day within samples taken from various ecological systems including the human body. MTPS will serve as the backbone of the center’s research efforts. Although MTPS is generally applicable to all non-electrophoretic sequencing technologies, Metabiomics™ LLC and MBAC are presently using pyrosequencing as the platform of choice for the most cost effective high throughput DNA sequencing platform for MultiTag Sequencing™.
“MultiTag Sequencing™ (MTS) can revolutionize the study of microbial communities,” says Gillevet. Before this technology was developed, we would have been hard-pressed to identify a couple hundred of microbes per sample. Now, we are identifying 50,000 or 60,000 microbes per sample. We can literally do in an afternoon what it took us 10 years to do in the past.”
Dr. Gillevet explains that, “It’s a new tactic to actually characterize the human microbiome or population of microorganisms living within the human body and correlate it with disease states and changes within the immune system. He goes on to say that “Finding the microbes and dysfunctional microbial systems responsible for particular diseases may increase the likelihood of developing new diagnostic tests and treatments for them.”
The collaborative research at MBAC is currently supported by grants from the Department of Defense and NIH, Gillevet’s team is currently collaborating with researchers at Metabiomics LLC and Rush University Medical Center in Chicago to chart the presence of microorganisms in patients suffering from breast cancer, Crohn’s Disease, inflammatory bowel disease, cirrhosis of the liver and HIV, and other collaborative research lines.
Dr. Thomas Kuehn, President of Metabiomics™ LLC, pointed out that Metabiomics™ LLC has an on-going exclusive agreement to commercialize the results of MBAC research. “We are now looking to forge partnerships with biotechnology and pharmaceutical firms to accelerate the development and clinical trials of new diagnostic and therapeutic products based on applying this new science of MultiTag Sequencing™ to the rapid discovery the secrets of the human microbiome.”
MultiTag Sequencing™ Services Now Available for Genomics Research Applications
Manassas, VA (April 15, 2009) -- Metabiomics™ LLC is now offering the human Genomics research community advanced MultiTag Sequencing™ primers and services including a limited license to use its patent pending MultiTag Sequencing™ method for research purposes. This breakthrough MultiTag Sequencing™ invention relates to multiplex polynucleotide sequence analysis using massively parallel sequencing methods, such as pyrosequencing methods and sequencing by synthesis. The invention provides increased throughput and the ability to analyze greater numbers of samples simultaneously or serially on presently available systems, as well as others yet to be developed. The invention is important for increasing the productivity of DNA analysis of complex microbial communities, particularly to in-depth analysis thereof in large numbers of samples.
Contact us for more info
| 